Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD acquired a new position in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 54,585 shares of the biotechnology company's stock, valued at approximately $8,340,000.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD purchased a new position in Biogen during the 4th quarter worth approximately $2,860,000. Hopwood Financial Services Inc. purchased a new position in shares of Biogen during the 4th quarter valued at $46,000. EverSource Wealth Advisors LLC grew its holdings in shares of Biogen by 662.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,448 shares of the biotechnology company's stock valued at $221,000 after acquiring an additional 1,258 shares in the last quarter. Sequoia Financial Advisors LLC grew its holdings in shares of Biogen by 31.7% during the 4th quarter. Sequoia Financial Advisors LLC now owns 3,026 shares of the biotechnology company's stock valued at $463,000 after acquiring an additional 729 shares in the last quarter. Finally, Moors & Cabot Inc. grew its holdings in shares of Biogen by 19.2% during the 4th quarter. Moors & Cabot Inc. now owns 1,335 shares of the biotechnology company's stock valued at $204,000 after acquiring an additional 215 shares in the last quarter. 87.93% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of research analysts have weighed in on BIIB shares. Stifel Nicolaus lowered shares of Biogen from a "buy" rating to a "hold" rating and set a $175.00 target price for the company. in a research report on Monday, December 16th. Mizuho cut their target price on shares of Biogen from $251.00 to $207.00 and set an "outperform" rating for the company in a research report on Thursday, November 21st. Truist Financial cut their target price on shares of Biogen from $220.00 to $210.00 and set a "buy" rating for the company in a research report on Thursday, February 13th. Citigroup cut their target price on shares of Biogen from $160.00 to $145.00 and set a "neutral" rating for the company in a research report on Thursday, February 13th. Finally, William Blair reissued an "outperform" rating on shares of Biogen in a research report on Monday, January 13th. Seventeen analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat, Biogen has a consensus rating of "Hold" and a consensus target price of $213.33.
Read Our Latest Stock Report on BIIB
Biogen Stock Performance
NASDAQ BIIB opened at $143.66 on Wednesday. Biogen Inc. has a 1 year low of $128.51 and a 1 year high of $238.00. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.35 and a quick ratio of 0.90. The firm has a market cap of $21.03 billion, a price-to-earnings ratio of 12.84, a PEG ratio of 1.51 and a beta of 0.01. The company has a fifty day moving average price of $143.80 and a 200-day moving average price of $165.37.
Biogen (NASDAQ:BIIB - Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share for the quarter, beating the consensus estimate of $3.43 by $0.01. Biogen had a net margin of 16.87% and a return on equity of 14.98%. As a group, equities research analysts predict that Biogen Inc. will post 15.83 EPS for the current fiscal year.
Insiders Place Their Bets
In other news, Director Stephen A. Sherwin sold 8,760 shares of the stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $150.02, for a total value of $1,314,175.20. Following the sale, the director now directly owns 11,318 shares of the company's stock, valued at approximately $1,697,926.36. This represents a 43.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.16% of the company's stock.
About Biogen
(
Free Report)
Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Biogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biogen wasn't on the list.
While Biogen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
